Telmisartan Production Cost Reports

The report provides a detailed analysis essential for establishing a Telmisartan production plant. It encompasses all critical aspects necessary for Telmisartan production, including the cost of Telmisartan production, Telmisartan plant cost, Telmisartan production costs, and the overall Telmisartan production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Telmisartan production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Telmisartan is an antihypertensive medication primarily used in the pharmaceutical industry as an active ingredient for treating high blood pressure (hypertension), heart failure, and diabetic kidney disease. It acts as an angiotensin II receptor blocker (ARB), preventing vasoconstriction and volume expansion by inhibiting the binding of angiotensin II to its receptor, thereby lowering systemic vascular resistance and blood pressure.

Telmisartan also functions as a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ), which may improve insulin sensitivity and provide protective benefits against vascular and renal damage, mainly in diabetic and cardiovascular conditions. It is mainly formulated into oral tablets and is also available in combination therapies with other antihypertensive agents.

The telmisartan market is primarily driven by the global rise in cases of hypertension and cardiovascular diseases, which are major public health concerns worldwide. Rising geriatric populations, who are more susceptible to hypertension, contribute significantly to its increased demand. The adoption of fixed-dose combination therapies involving Telmisartan enhances treatment efficacy and patient adherence, further fuelling market growth. Additionally, expanding healthcare infrastructure, increased healthcare spending, and rising health awareness, especially in regions like the Asia Pacific and North America, support market expansion.

Ongoing pharmaceutical innovations in drug formulations, potential new indications such as diabetic kidney disease, and favourable government policies for hypertension management further contribute to its demand. However, patent expirations and stringent regulatory environments for generics present challenges to market growth and impact the overall industrial telmisartan procurement.

Raw Material for Telmisartan Production

According to the Telmisartan production plant project report, the various raw materials for Telmisartan production include 2-(2-bromophenyl)-4,4-dimethyl-2-oxazoline and 4-formylphenylboronic acid.

Production Process of Telmisartan

The extensive Telmisartan production cost report consists of the following major industrial production process:

1. Production via Suzuki coupling reaction: The production process of Telmisartan involves a key Suzuki coupling reaction between 2-(2-bromophenyl)-4,4-dimethyl-2-oxazoline and 4-formylphenylboronic acid. The reaction occurs in the presence of aqueous sodium carbonate and tetrakis(triphenylphosphine)palladium(0) catalyst in THF solvent, yielding the biaryl aldehyde intermediate. This intermediate undergoes reductive amination with a prepared amine, followed by in situ cyclisation to form the n-propyl benzimidazole derivative. The oxazoline moiety is finally cleaved by acid to yield Telmisartan as the final product.

Properties of Telmisartan

Telmisartan is a white or off-white crystalline powder with no odour or taste. Its molecular formula is C33H30N4O2, and it has a molecular weight of 514.62 g/mol. It is practically insoluble in water, slightly soluble in methanol, very slightly soluble in acetone, and soluble in chloroform. It is also slightly soluble in 0.1 mol/L hydrochloric acid and soluble in 0.1 mol/L sodium hydroxide. Telmisartan exhibits polymorphism and has high lipophilicity, contributing to its pharmacokinetic properties. The compound has a high plasma protein binding rate of over 99.5%, mainly binding to albumin. The melting point is reported to be above 220 degree Celsius. It has seven rotatable bonds and one hydrogen bond donor, with a topological polar surface area of 72.94 Ų and a high logP value (~7.7), indicating strong lipophilicity.